Patients between 18 and 75 years of age Patients with inflammatory bowel disease (Crohn's disease (CD) or ulcerative colitis (UC)) Patient with poorly controlled type 2 diabetes (defined as deviation from the set glycemic target of more than 1% HbA1c) Patient with a BMI ≥ 25 kg/m2  For women of childbearing age: effective contraception* during treatment and up to 5 weeks after discontinuation  * Any contraceptive method used regularly and appropriately that has a low failure rate (i.e., less than 1% per year)  Patient enrolled in a health insurance plan Francophone patient Patient with free, informed, written consent  Exclusion Criteria:  Patient with a personal or family history of medullary thyroid cancer Patient with an active cancer Patient with a history of acute or chronic pancreatitis Patients with a history of hypersensitivity to GLP1 analogues (or to any other component of the product) Patient with a history of severe GI intolerance to GLP-1 receptor agonists Patient already included in a risky interventional research protocol (RIPH1) Pregnant or breastfeeding women Patients with congestive heart failure New York Heart Association (NYHA) class IV Patient with end-stage renal disease Patients with clinically significant sustained elevation of resting heart rate Patient with anti-GAD antibodies in a previous workup at inclusion Patient under guardianship or curatorship Patient under court protection Patient deprived of liberty